TSAIII up-regulated the acetylcholine contents, inhibited the AChE activity and decreased the expression of TNF-α and IL-1β in scopolamine-treated mice brain models [38], meaning that TSAIII may be across the blood–brain barrier (BBB) in Alzheimer’s disease. The gene discussed is TNF; the disease is early-onset autosomal dominant Alzheimer disease.